Adagene Inc.
muzastotug
microsatellite stable colorectal cancer (MSS CRC)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on muzastotug for microsatellite stable colorectal cancer (MSS CRC) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“the FDA to initiate the a potential registrational study of muzastotug pending further FDA feedback regarding the dose regimen identified from ongoing trials.”